Picture of AbCellera Biologics logo

ABCL — AbCellera Biologics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

Abcellera Biologics Inc reports results for the quarter ended in September - Earnings Summary

* Abcellera Biologics Inc  ABCL.OQ  reported quarterly
adjusted
earnings of 8 cents​​ per share for the quarter ended in
September. The mean expectation of seven analysts for the
quarter was for earnings of 5 cents per share.
    * Revenue rose 1,740.6% to $101.38 million from a year ago;
analysts expected $74.95 million. 
    * Abcellera Biologics Inc's reported EPS for the quarter was
8
cents​.
    * The mean earnings estimate of analysts had risen by
about 269.1%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * Abcellera Biologics Inc shares had risen by 21.4% this
quarter and lost 16.0% so far this year.
    * The company reported quarterly net income of $26.62
million.
    * Wall Street's median 12-month price target for Abcellera
Biologics Inc is $32.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
8 at 11:17 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      0.05           0.08           Beat
 Jun. 30 2022      -0.02          -0.02          Met
 Mar. 31 2022      0.38           0.54           Beat
 Dec. 31 2021      0.19           0.19           Met

Recent news on AbCellera Biologics

See all news